Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials

KIORA PHARMACEUTICALS INC

2024-Q2 EPS reported $2.79 revenue$16,020,000

Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.
Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.
Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.
Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.
Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.